Trial Profile

Evaluate the Efficacy and Safety of HLX10, PD-1 mAb, in Combination With HLX07, EGFR mAb, in Patients With Advanced Head And Neck Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimurutamab (Primary) ; Serplulimab (Primary) ; Carboplatin; Cisplatin; Fluorouracil
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Henlius Biotech

Most Recent Events

14 Feb 2023 Protocol of study has been amended to add double blind part 2 in study , to increase treatment arm to 4 .
14 Feb 2023 Planned number of patients changed from 56 to 131.
14 Feb 2023 Planned End Date changed from 31 Oct 2023 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com